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HIV-1 accumulates mutations in and around reactive epitopes to escape recognition and killing by CD8+ T cells. 
Measurements of HIV-1 time to escape should therefore provide information on which parameters are most 
important for T cell–mediated in vivo control of HIV-1. Primary HIV-1–specific T cell responses were fully 
mapped in 17 individuals, and the time to virus escape, which ranged from days to years, was measured for each 
epitope. While higher magnitude of an individual T cell response was associated with more rapid escape, the 
most significant T cell measure was its relative immunodominance measured in acute infection. This identified 
subject-level or “vertical” immunodominance as the primary determinant of in vivo CD8+ T cell pressure in 
HIV-1 infection. Conversely, escape was slowed significantly by lower population variability, or entropy, of the 
epitope targeted. Immunodominance and epitope entropy combined to explain half of all the variability in time 
to escape. These data explain how CD8+ T cells can exert significant and sustained HIV-1 pressure even when 
escape is very slow and that within an individual, the impacts of other T cell factors on HIV-1 escape should be 
considered in the context of immunodominance.
Introduction
HIV-1–specific CD8+ T cells are central to anti–HIV-1 immunity 
(1–6). HIV-1–specific CD8+ T cells are first detected prior to peak 
plasma viremia around 2 to 3 weeks after infection, expand as virus 
load (VL) declines, and thereafter can be detected throughout 
chronic infection (3). However, observations that strong HIV-1–
specific T cell responses can be detected both in adults who are 
controlling HIV-1 well as well as in many of those progressing to 
AIDS (7) suggests that not all specific CD8+ T cell responses are 
equal and that some control virus better than others.
The parameters that distinguish the more effective CD8+ T cells, 
particularly in acute HIV-1 infection, are not clear but are likely 
to be influenced strongly by their epitope specificity. Comprehen-
sive mapping of HIV-1–specific T cell responses is limited by the 
sequence diversity of HIV-1, with most studies in chronic infection 
using clade consensus peptide sets that fail to detect a significant 
proportion of T cell responses (8). Even so, large cross-sectional 
studies have found that subjects whose CD8+ T cells preferentially 
target the structural protein Gag are more likely to sustain lower 
VL in chronic HIV-1 infection (9). The importance of epitope 
specificity to virus control is also suggested by genetic studies that 
found lower VL and delayed disease progression associated with 
the expression of certain HLA alleles, B*57/5801, B*27, B*51, and 
B*8101 (10–12), and the finding that protection is linked to the 
number of T cell responses restricted by these HLA types (13).
The specificity of the T cell response is determined by multi-
ple parameters, including HLA, virus sequence, and T cell recep-
tor repertoire (14–16). When more than one epitope is targeted, 
responding populations expand unevenly, establishing a vertical 
immunodominance hierarchy within a subject. Vertical T cell 
immunodominance patterns are highly variable among subjects 
and change over time, largely as a consequence of the sequence 
variability of HIV-1 (17–20). This differs from horizontal immu-
nodominance, also described as immunoprevalence (21), in which 
the same reactive epitope is commonly targeted by individuals 
of a given HLA type at the population level. Horizontally immu-
nodominant epitopes often are not vertically immunodominant 
(22, 23). Studies of HIV-1 infection have identified several HLA 
allotypes that present epitopes that are consistently horizontally 
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immunodominant (1), with some, associated with protection (1, 
24). While horizontal HIV-1–specific T cell immunodominance 
has been broadly investigated, until recently, there has been lim-
ited information on vertical CD8+ T cell immunodominance 
hierarchies in HIV-1 infection (13, 20, 25). We propose that the 
true contribution of epitope specificity and relative immunodom-
inance of CD8+ T cells to control of HIV-1 infection can only be 
understood when all T cell responses are measured.
In response to CD8+ T cell pressure, HIV-1 mutates to escape 
recognition (26–29). Virus escape begins almost as soon as CD8+ 
T cell responses appear, coincident with acute VL decline (19, 
20, 26, 29). Complete escape from primary HIV-1–specific CD8+ 
T cells can occur in only 10 days from first detection of a T cell 
response (20, 30). Modeling studies, which assumed that higher 
rates of virus escape are representative of greater killing efficiency 
by HIV-1–infected cells, calculated that T cells specific for a sin-
gle epitope could contribute >30% of the killing of infected CD4 
T cells per day while virus escape was ongoing (20, 31).
In addition to T cell killing of virus-infected cells, another fac-
tor impacting rate of virus escape is the replicative capacity of 
the emerging mutant virus(es), specifically whether the fitness 
costs of escape could themselves slow that rate of escape (32). 
Evidence that T cell selected HIV-1 escape can confer fitness 
costs to the virus in vivo comes from the consistent reversion of 
escaped virus when transmitted into patients with different HLA 
types (33, 34). Documented examples of reversion are limited to 
a few well-described epitopes, but in vitro studies of particu-
lar epitopes have repeatedly shown lower replication following 
introduction of HIV-1 T cell escape mutations into chimeric or 
full-length viruses (35–38). Both types of study have focused on 
epitopes presented by protective HLA, with limited fitness cost 
information available on the vast majority of epitopes.
Recently, in 5 subjects we observed a correlation between the 
rank order of escape within patients and the Shannon entropy 
of the epitope (39). Shannon entropy (40) can be used to mea-
sure population diversity at a given sequence position or within 
a cluster of bases/amino acids, such as an epitope seen by CD8+ 
T cells. HIV-1 is highly variable at the population level, but some 
regions of the virus are more conserved (41). Low entropy val-
ues correspond to sites that are more conserved (42), and HIV-1 
T cell epitopes with lower average entropy escaped more slowly 
(39). These observations suggested that entropy, which can be 
calculated for any epitope, can be used as a surrogate measure of 
the fitness cost of escape.
Here, in a larger cohort, we used epitope entropy in combina-
tion with measurements of T cell selection pressure to show that 
CD8+ T cells can exert significant in vivo pressure on HIV-1, even 
when the subsequent virus escape is very slow. We examined the 
complete T cell response to HIV-1 in 17 patients, using peptides 
matched to both the autologous founder virus sequence and sub-
sequent evolutionary variants. This enabled us to define the verti-
cal immunodominance profiles in each patient and to show clear 
changes in patterns of immunodominance during the first several 
months of infection, clearly related to evolutionary pressure on 
the virus sequence. We found, in multivariate analysis, that the 
time taken for HIV-1 to escape each of the first T cell responses 
is determined largely by the combination of the relative immu-
nodominance of the T cell response and the fitness constraints 
on variability within the epitope (relative risk [RR] = 6.6, P = 6.4 
× 10–8). The measure of immunodominance alone explained 39% 
of the variation in time to virus escape. This highly significant 
risk ratio means that the role of other factors that include poly-
functionality and T cell exhaustion in influencing escape rate are 
unlikely to work independently of immunodominance. This study 
gives insight into how pressure is exerted by CD8+ T cells on HIV-1 
and why it changes rapidly during early infection.
Results
Shifts in T cell immunodominance hierarchies are observed early in HIV-1 
infection. We studied a cohort of 17 patients infected acutely with 
HIV-1. Five subjects, four with protective HLA types (B*57, 5801, 
and 81), exhibited early virus control, with mean VL <5,000 vRNA 
copies per ml for up to 2 years following infection (Figures 1, 2, 
and 3, and Table 1). The others had more typical VL set points, 
ranging from 5,811 to 575,440 vRNA copies per ml. One subject, 
CH607, started on antiretroviral therapy (ART) within 2 months 
of infection; the others did not receive ART during this study, in 
line with local medical guidelines. The transmitted/founder (T/F) 
virus in each subject was deduced following single genome ampli-
fication (SGA) and sequencing of plasma virus taken in acute 
infection close to peak viremia (43). Fifteen subjects were infected 
with a single T/F virus (data not shown). Two subjects, CH159 
and CH607, were each infected with 2 very closely related viruses, 
differing by 2 and 13 nucleotides, respectively. SGA sequencing 
of virus was repeated in most subjects at frequent intervals in the 
first 3 months of infection and then less frequently in the ART 
naive subjects over 1 to 3 years (Figures 1–3). This revealed sites, 
or clusters of sites, in which nonsynonymous (ns) mutations were 
selected by immune responses in each subject (Supplemental Fig-
ure 1; supplemental material available online with this article; 
doi:10.1172/JCI65330DS1).
Overlapping peptides matched to the full proteome of the T/F 
virus(es) in each subject were synthesized, and T cell responses 
were mapped using ex vivo IFN-γ ELISpot assays. Acute anti–HIV-1 
T cell responses were therefore measured without bias to known 
epitopes; indeed only 43% of all T cell responses mapped to pre-
viously described or predicted epitopes (Figures 1–3 and Supple-
mental Table 1). Our previous studies have found that nearly all 
T cell responses in patients with acute HIV-1 infection measured 
in this way were mediated by CD8+ T cells (20, 39).
T cell responses were first detected around peak viremia and 
were typically narrow (median of 3 epitopes, range 1–11). The 
magnitude of individual T cell responses measured by ELISpot 
was used to rank T responses and define immunodominance 
hierarchies within subjects. Different hierarchies were observed, 
coincident with VL decline from peak viremia (Figures 1–3). The 
dominant or most highly ranked T cell responses were mostly 
focused on the Nef, Env, and Gag proteins while Pol was targeted 
infrequently (Figure 4A) (44). The strong, early Nef-specific T cell 
responses (Figure 4B) were consistent with previous observations 
(25, 45). In as little as a week, shifts in T cell immunodominance 
hierarchies were observed, often following rapid decline of the first 
T cell responses as virus escaped (Figures 1–3). By 6 months fol-
lowing infection, additional HIV-1–specific T cell responses had 
emerged in most subjects (16 ART naive subjects: median number 
of epitopes targeted at 6 months = 6, range 2–16) (17–20). In the 7 
subjects expressing HLA B*57/*5801 or B*8101, T cell responses 
restricted by these protective HLA alleles were dominant within 
weeks of infection but were often not the first dominant response 
(Figures 1–3 and Supplemental Table 1).
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HIV-1 escape from CD8+ T cells occurs at very different rates – from 
days to years. We focused on HIV-1 escape from the first T cell 
responses detected within 50 days of estimated time Fiebig 
stages I/II. Fiebig categories, which range from Fiebig stage I–VI, 
classify stages of acute HIV-1 infection in accordance with reac-
tivity in diagnostic assays (46). Fiebig stages I/II, when subjects 
are HIV-1 vRNA positive but seronegative, broadly corresponds 
to acute VL ramp up shortly before peak viremia is observed 
(47). The following 50-day phase occurs coincident with acute 
plasma VL decline and early onset of VL set point (ref. 3 and 
Figures 1–3). This window is likely to be crucial in determining 
subsequent VL control. Frequent blood sampling in this period 
enabled detailed measurement of T cell responses to T/F and 
mutant viruses, T cell immunodominance hierarchies, and virus 
sequence changes. We would note that while high VLs were mea-
sured in the first 50 days from Fiebig stages I/II (Figures 1–3), 
our weekly sampling schedule was insufficient to track the rap-
idly changing acute VL kinetics and confidently calculate peak 
viremia in our subjects. Similarly, while acute VL decline was 
observed in most subjects (Figures 1–3), without a peak viremia 
measurement, we were unable to calculate VL slopes. Our anal-
yses were therefore focused on understanding how HIV-1–spe-
cific T cell responses in this critical acute stage of HIV-1 infec-
tion exert antiviral pressure and select escape mutants.
Virus escape from CD8+ T cells was first identified by ns changes 
in reactive T cell epitopes over time. In most cases, escape was then 
examined experimentally by comparing peptides containing the 
mutant amino acid sequences with their corresponding reactive 
T/F peptide. T cell recognition of the mutant peptides was gener-
ally impaired compared with peptides matching the T/F sequence 
(Supplemental Table 1). Also, 3 examples were found of mutations 
adjacent to an invariant T cell epitope that coincided with loss of 
the T cell response; these mutations probably impaired antigen 
processing (AgP) (ref. 48 and Supplemental Table 1). Limited 
blood volumes precluded experimental confirmation of these 
putative AgP escapes, so subsequent analyses are presented with 
and without their inclusion.
Extending earlier results in 3 of these subjects (20), early rapid 
escape from the first CD8+ T cells induced following HIV-1 infec-
tion was observed in one or more epitopes in all subjects (Supple-
mental Figure 1). Overall, in 15 subjects, T cell escape occurred in 
the first 50 days from Fiebig stages I/II and in 2 subjects within 
the first 70 days (Supplemental Table 1). In contrast with previ-
ous observations (49), rapid virus escape was not more common 
in epitopes restricted by protective HLA allotypes (Figures 1–3 and 
Supplemental Table 1). Our observations showed clearly that when 
comprehensive T cell mapping is performed, rapid HIV-1 escape 
was measured in T cell epitopes restricted by a broad range of HLA 
Figure 1
Shifting immunodominance of CD8+ T cell responses 
induced in early HIV-1 infection. Subject CH131 was 
detected in acute HIV-1 infection (Fiebig stages I/II), 
just prior to peak viremia. HIV-1–specific CD8+ T cell 
responses in PBMCs were mapped using ex vivo IFN-γ 
ELISpot against autologous, overlapping peptides span-
ning the subject’s T/F virus (solid colored lines). Distinct 
CD8+ T cell immunodominance was observed as early 
as peak viremia (red dotted line). See inset for greater 
detail. Above the panel, the blue text indicates the days 
from Fiebig stages I/II when SGA sequencing was per-
formed. Sequence at day 0 was used to deduce the T/F 
and subsequent sequencing used to track emerging ns 
mutations in the virus population. Below this text, colored 
bars represent the changes in the epitope sequence 
of the corresponding (color-matched) T cell response, 
with black vertical lines showing days to 50% T/F virus 
sequence. As the virus escapes, T cell responses often 
decline, after which new or subdominant T cell responses 
become immunodominant. The HXB2 location of each 
reactive peptide epitope and, if known, the HLA restriction 
is identified to the left of the bar. A positive T cell response 
required a background subtracted response of >30 SFU 
per million PBMCs and >4× background.
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allotypes, not limited to HLA allotypes associated with lower VLs. 
Mathematical modeling (20) showed that, within each subject, 
individual T cell responses killed up to 50% of infected CD4+ T cell 
targets per day (Supplemental Table 1). By shortening the life 
span of productively infected cells 
in vivo, acutely responding CD8+ 
T cells exerted substantial antiviral 
pressure in all patients studied.
In addition to T cells selecting 
rapid escape, there were an equal 
number of T cell responses specific 
for epitopes that varied very little 
during the first 50 days of observa-
tion (Figure 4C and Supplemental 
Figure 1). However, most of these 
epitopes escaped in the first year 
following infection, 70% within the 
first 6 months (Figure 4C). Only 
14% of T epitopes remained invari-
ant throughout the whole period 
of observation (sequencing 350–
1,187 days from Fiebig stages I/II). 
Therefore, the large majority of 
HIV-1 epitopes recognized by CD8+ 
T cells escape, but, within the same 
patient, the time taken ranges from 
days to years (Figure 4C). Estimates, 
using existing mathematical mod-
els (31), of killing by HIV-1–specific 
CD8+ T cells selecting slow escape 
were much lower than for the 
rapid escapes (Supplemental Table 1). Among the slow-escaping 
epitopes, several were restricted by protective HLA alleles (Supple-
mental Table 1). Given the strong association of these HLA types 
with lower VL, we would predict that these T cell responses exert 
Figure 2
HIV-1–specific CD8 T cell kinet-
ics. T cell kinetics in subjects (A) 
CH067, (B) CH058, (C) CAP045, 
(D) CH198, (E) CH077, (F) CH159, 
and (G) CH040 with VL set points 
from 40–14,791 copies/ml (red dot-
ted line). HIV-1–specific CD8+ T cell 
responses in PBMCs were mapped 
using ex vivo IFN-γ ELISpot against 
autologous, overlapping peptides 
spanning the subject’s T/F virus 
(solid colored lines). Above each 
panel, the blue text indicates the 
days from Fiebig stages I/II when 
SGA sequencing was performed. 
Below this text, colored bars rep-
resent the changes in the epitope 
sequence of the corresponding 
(color-matched) T cell response, 
with black vertical lines showing 
days to 50% T/F virus sequence. 
The HXB2 location of each reactive 
peptide is identified to the left of the 
bar, and HLA restriction (if known) 
is identified to the right. A positive 
T cell response required a back-
ground subtracted response of >30 
SFU per million PBMCs and >4× 
background.
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Figure 3
HIV-1–specific CD8 T cell kinetics continued. T cell kinetics in subjects (A) CH256, (B) CH470, (C) CAP239, (D) CH185, (E) CH162, (F) CH042, 
(G) CAP210, and (H) CH164, with VL set points from 18,621–575,440 copies per ml (red dotted lines). HIV-1–specific CD8+ T cell responses in 
PBMCs were mapped using ex vivo IFN-γ ELISpot against autologous, overlapping peptides spanning the subject’s T/F virus (solid colored lines). 
Above each panel, the blue text indicates the days from Fiebig stages I/II when SGA sequencing was performed. Below this text, colored bars rep-
resent the changes in the epitope sequence of the corresponding (color-matched) T cell response, with black vertical lines showing days to 50% 
T/F virus sequence. The HXB2 location of each reactive peptide is identified to the left of the bar and HLA restriction (if known) is identified to the 
right. A positive T cell response required a background subtracted response of >30 SFU per million PBMCs and more than 4 times background. 
Subject CH607 went onto ARV approximately 5 weeks after Fiebig stages I/II. Therefore, T cell kinetics were not followed.
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significant in vivo immune pressure. In the light of our previous 
observation of little functional variability in acutely responding T 
cells, irrespective of rate of virus escape (39), this suggests that slow 
escape does not equate to poor ongoing immune pressure (32). We 
therefore asked whether other factors impacted time to escape.
T cell response magnitude, immunodominance rank, and breadth are 
significantly associated with time to virus escape. We examined the 
parameters that contribute to time to virus escape, anticipating 
that this approach would give us a measure of the antiviral pres-
sure exerted by CD8+ T cells. Given the contribution of T cell 
immunodominance hierarchies in antiviral immunity in mouse 
models (14), we first sought correlations between T cell magni-
tude and relative immunodominance and time to virus escape 
in each epitope (see Methods for definition of time to escape). 
Data were examined in terms of “survival” of the founder T cell 
epitope, fitting Cox proportional hazards (CPH) models to cal-
culate RR of escape in nonstratified and subject-stratified data. 
Significance tests examined the null hypothesis that the covari-
ate being tested had no impact on escape, i.e., RR = 1.
RR calculations found that increases in the log10 of the absolute 
magnitude (M) of individual T cell responses significantly increased 
the risk of virus escape (RR = 3.3, P = 0.03; Table 2), consistent with 
our previous rank order observations in a smaller data set (39). Our 
larger and more detailed data sets enabled us to express data for 
each patient as a percentage magnitude (%M) of the total T cell 
response measured by IFN-γ ELISpot at the given time point. %M 
Table 1
Demographic and clinical data from study subjects
Subject Gender (M/F) CountryA Age at first HIV-1 Median CD4 Virus set pointC HLA type
identifier   positive HIV-1 subtype countB  (copies vRNA/ml)
   vRNA (yr)   (cells/μl)
CH067 F S. Africa 32 C 1,557 40 A*01:01,A*33:01, B*53:01,B*81:01, 
        Cw*04:01,Cw*18:01
CH058 M USA 23 B 861 234 A*01:01,A*23:01, B*14:02,B*57:01-04, 
        Cw*07:01,Cw*08:02
CAP045 F S. Africa 41 C 1,046 871 A*23:01,04, A*29:02,03, B*15:10,B*45:01, 
        Cw*16:01,Cw*16:02
CH198 M S. Africa 33 C 894 1,175 A*03:01,A*74:01, B*08:01,B*57:01-04, 
        Cw*07:01,Cw*07:02
CH077 M USA 23 B 756 3,631 A*02:05,A*02:05, B*53:01,B*57:01-04, 
        Cw*04:01,Cw*18:01
CH159 F Malawi 18 C 440 8,511 A*23:01,A*6802, B*81:01,B*18:01, 
        Cw*07:04,Cw*18:01
CH040 M USA 56 B 986 14,791 A*31:01,A*02:01, B*44:02,B*40:01, 
        Cw*03:02,Cw*05:01
CH256 F Malawi 19 C 601 18,621 A*33:01,A*68:01, B*14:01,B*53:01, 
        Cw*04:01,Cw*08:02
CH131 M Malawi 20 C 300 22,909 A*29:01-04,A*23:01, B*45:01,B*15:03, 
        Cw*02:02,Cw*06:02
CH470 M USA 17 B 470 23,710 A*03:01,A*01:01, B*08:01,B*49:01, 
        Cw*07:01,Cw*07:01
CAP239 F S. Africa 44 C 792 26,915 A*01:01,A*29:02,03, B*42:01,B*58:01, 
        Cw*06:02,Cw*07:02,03
CH185 F S. Africa 20 C 309 40,738 A*01:01,A*74:01, B*15:03,B*81:01, 
        Cw*02:02,Cw*18:01
CH162 M S. Africa 42 C 376 114,815 A*34:02,A*30:01, B*44:03,B*42:02, 
        Cw*04:01,Cw*17:01
CH042 M S. Africa 38 C 349 128,825 A*23:01,A*30:02, B*15:03,B*18:01, 
        Cw*02:02,Cw*07:04
CAP210 F S. Africa 43 C 306 295,121 A*68:02,A*68:02, B*15:10,B*15:10, 
        Cw*03:04,Cw*03:04
CH164 M S. Africa 27 C 447 575,440 A*02:01,A*29:01-04, B*44:03,B*45:01, 
        Cw*07:01,Cw*16:01
CH607 M USA 18 B 984D –D A*03:01,A*01:01, B*08:01,B*49:01, 
        Cw*07:01,Cw*07:01
AAll African subjects are black Africans. The USA subjects, CH040, CH470, and CH607, are of mixed European descent, and subjects CH058 and CH077 are 
African American. BCD4 count calculated from available time points (minimum 2) from visits between 6 months to 1 to 3 years following subject screening. 
CHIV-1 viral load set point calculated as described in Fellay et al. (2). Briefly, data were manually inspected, and outliers and time points in either the acute 
stage of infection or following progression were excluded. Set point was the average of all remaining results. DSubject CH607 received ART from approxi-
mately 5 weeks from Fiebig stages I/II. Bolded underlined text identifies HLA alleles associated with lower VL set points and or delayed progression to HIV-1–
related disease. F, female; M, male; S. Africa, South Africa.
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was our operational measure of immunodominance, providing 
both the proportional contribution of each T cell response and its 
rank in its immunodominance hierarchy in acute HIV-1 infection. 
Importantly, calculation of %M in this study enabled comparisons 
across all subjects not examined in our previous study (39). The 
impact of %M of T cell responses measured in acute infection on 
non-subject stratified data were highly significant (RR = 3.6, P = 5.5 
× 10–5; Table 2). The correlation improved for both M and %M when 
probable AgP mutations were included (%M: RR = 5, P = 7.5 × 10–7; 
Table 2). Data resolved into tertiles are shown in survival plots in 
Figure 5, A and B. These plots illustrate that the greatest effect of 
M and %M on time to escape came from data falling into the high-
est tertile, i.e., the highest magnitude (>320 SFU/106 PBMCs) and 
the most dominant T cell responses (>33%). The greater the M and 
the higher the position of the T cell response in the immunodomi-
nance hierarchy, the more rapidly virus escape was selected.
The breadth of the HIV-1–specific T cell response measured in 
acute infection also had a significant effect on RR of virus escape 
(RR = 0.85, P = 0.0027). Given that breadth is a subject-level mea-
sure, RR analyses, again using CPH tests, were limited to non-sub-
ject stratified data (Table 2 and Figure 5C). Consistent with pre-
vious predictions from mathematical modeling (31), higher T cell 
breadth in acute HIV-1 infection (n > 3) correlated with a slower 
rate of escape from individual T cell responses within a subject.
Shannon entropy of the epitope influences the rate of virus escape. In our 
data set, some epitopes (e.g., B*81-restricted Gag 180-188 TL9 in 
subjects, CH067, CH159, and CH185; Figure 2, A and F; Figure 
3D; and Supplemental Table 1), despite becoming immunodom-
inant very early in infection, selected escape slowly over months 
to years. This suggested that while overall dominant T cell 
responses were the most effective at recognizing and killing 
virus-infected cells, virus-intrinsic factors were retarding the abil-
ity of mutant viruses to emerge. In this much larger data set than 
our previous analysis (39), we again used Shannon entropy (40) 
as a measure of the variability of each epitope at the population 
level to assess associations with time to escape. Our mapping 
studies had identified T cell epitopes to the level of a reactive 
18-mer peptide. In more than a half of cases, we went further and 
experimentally identified the optimal T cell epitope (Figures 1–3 
and Supplemental Table 1). We initially limited studies of entropy 
and time to escape to optimal epitopes. A significant correlation 
between Shannon entropy values for the optimal epitopes and 
time to escape was observed in CPH models; the more conserved 
the epitope at a population level, the slower the escape (n = 34, 
RR = 6.6, P = 0.017). Notably, mapped epitopes restricted by pro-
tective HLA alleles B*57/5801 and B*8101 had lower entropies 
compared with epitopes restricted by HLA alleles not associated 
with protective effects on VL (P = 0.03, Mann-Whitney 1 tailed; 
Supplemental Table 1 and Supplemental Figure 2).
The analysis was then expanded by calculating entropies for 
reactive peptides in which the optimal 8- to 11-mers T cell epitope 
had not been experimentally defined (see Methods and Supple-
mental Figure 3). Analysis of the larger data set found similarly 
that increased log10-transformed entropy scores increased the rate 
of virus escape (n = 59, RR = 4, P = 0.0099; Table 2). Tertile analy-
sis showed that the lowest entropy tertile, i.e., the most conserved 
epitopes (≤0.194 nats), escaped markedly more slowly (Figure 5D 
and Supplemental Table 2).
Multivariate analyses — T cell pressure and epitope entropy are 
independent predictors of escape. The univariate analyses above 
showed that T cell immunodominance (%M), M, breadth of 
the T cell response, and epitope entropy were all significantly 
Figure 4
The first HIV-1–specific CD8+ T cells tar-
get all HIV-1 proteins but are largely immu-
nodominant against Nef, Gag, and Envelope. 
(A) The total number and the proportion of 
mapped T cell epitopes found in each HIV-1 
protein that underwent escape in the first 50 
(blue), 100 (green), and 180 (red) days from 
Fiebig stages I/II. (B) The magnitude of each 
mapped T cell response was calculated as a 
percentage of the total response measured 
in that individual. Horizontal bars represent 
median values; each symbol represents an 
individual response. (C) Histogram binning 
time to escape for each epitope across sub-
jects in 50-day windows. The white blocks in 
columns indicate data adjusted to include 
putative AgP mutations (n = 3). Note that 
the median %M in B was higher for Nef than 
other proteins but was not significantly differ-
ent than Gag, Vif, and Env proteins (P > 0.05, 
1-way ANOVA Friedman test).
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correlated with the time to virus escape in acute HIV-1. Other 
subject-specific parameters were also tested but did not impact 
on the RR of virus escape; these included subject, gender, and 
age; continent of origin; infecting HIV-1 virus clade; and the 
virus set point (Supplemental Tables 3 and 4). Epitope-specific 
parameters were also analyzed. Neither expression of a protec-
tive HLA allele (B*57, B*58, B*81) nor Gag specificity of the 
T cell responses independently contributed to time to escape 
(Supplemental Tables 3 and 4).
Our large comprehensive data set provided us with a unique 
opportunity to next apply multivariate analysis to define the rela-
tive contributions of M, %M, T cell breadth, and entropy to time to 
escape. This approach produced a RR (and P value) for each covar-
iate and then assessed whether combining covariates produced a 
better “fit” when explaining time to escape. Two basic models were 
developed in which either M or %M were added to a model con-
taining entropy. Both M and %M significantly improved models 
of entropy (Table 3), and the overall P values of these models were 
highly significant (Table 3, bold text). The best fit was observed 
in the model of %M and entropy; the RR of each covariate was 
6.6, producing a combined model P value of 6.4 × 10–8 in non-
subject stratified data. We next accommodated extra variation in 
time to escape using multiple imputation methods (Supplemental 
Table 5). The results were the same as those from CPH models, 
suggesting that variation due to periodic sampling and differences 
in the number of SGA sequences available at different visits did 
not explain the associations observed. We also explored whether 
the effects between covariates were more than additive. No inter-
action was detected between M or %M and epitope entropy, consis-
tent with the hypothesis that the T cells exert pressure on the T/F 
virus, whereas epitope entropy relates more to the rate at which 
viral escape mutants emerge (Table 3).
Two additional more complex models, adding %M or T cell 
breadth to a model containing M and entropy, were developed. 
Adding %M as a covariate significantly improved the non-subject 
stratified models of M and entropy (P < 0.0001; Table 3) with-
out any interaction between %M and M (P > 0.05; Table 3). This 
observation was important as it showed that the position of a 
T cell response in the immunodominance hierarchy is indepen-
dent of its M and independently selects for more rapid virus escape, 
advancing our previous observations (39). In the next model, 
T cell breadth also significantly improved a model of M and entropy 
(P = 0.02; Table 3), with increased breadth slowing the emergence 
of viral escape mutants within a subject. As could be predicted, 
subjects whose first HIV-1 T cell responses included a highly dom-
inant (higher %M) T cell response had an overall lower total T cell 
breadth (r = –0.59, P = 0.01, Spearman 2 tailed). Given that these 
2 parameters were related, T cell breadth did not significantly add 
to multivariate models containing %M (data not shown). In sum-
mary, after rigorous statistical testing, %M and epitope entropy 
were identified as the major in vivo factors determining time to 
escape in acute HIV-1 infection.
Last, we calculated a coefficient of explained randomness (50) 
of the time to virus escape, which is analogous to explained vari-
ation (r2) for linear regression models. We observed that nearly 
half of the variation in time to escape was accounted for by just 
Table 2
Univariate testsA reporting RR of T cell response covariates, M, %M, T cell breadth, and entropy on time to T cell escapeB in epitopesC  
with and without putative AgPD
Cov Analysis TTE, TTE, TTE + AgP, TTE + AgP,
  unstratified subject stratified unstratified subject stratified
log10(M) RR/cov P 1.8/0.04 3.3/0.04 1.9/0.01 4.9/0.009
 (RR 95% CI) (1, 3) (1.1, 10) (1.2, 3.3) (1.5, 16)
 Model P value 0.042 0.03 0.015 0.0052
 n all, n eventsE 59, 49 59, 49 59, 52 59, 52
     
log10(%M) RR/cov P 3.6/1 × 10–4 3.2/0.04 5/4 × 10–6 4/0.02
 (RR 95% CI) (1.9, 6.8) (1, 9.8) (2.5, 9, 7) (1, 3, 13)
 Model P value 5.5 × 10–5 0.036 7.5 × 10–7 0.012
 n all, n events 57, 47 57, 47 57, 50 57, 50
     
BreadthF RR/cov P 0.87 – 0.85 –
 (RR 95% CI) (0.77, 0.98)  (0.76, 0.96) 
 Model P value 0.01  0.0027 
 n all, n events 59, 49  59, 52 
     
log10(entropy) RR/cov P 4/0.01 13/0.005 3.4/0.02 12/0.005
 (RR 95% CI) (1.4, 12) (2.2, 75) (1.2, 9.5) (2.1, 69)
 Model P value 0.0099 0.0024 0.019 0.0025
 n all, n events 59, 49 59, 49 59, 52 59, 52
ACox proportional hazards (CPH) tests. BTime to escape (TTE) measured in days from first detection of T cell response (detected in first 50 days 
from Fiebig stages I/II) to time to ≤50% transmitted virus within epitope. C17 subjects; total epitopes analyzed = 59. DTime to escape measured in 
days from first detection of T cell response to time to ≤50% transmitted virus, where mutation emerges within proximity of T cell epitope, occurring 
coincident with decline of T cell response. E “n all” refers to the total number of reactive epitopes. “n events” refers to the difference in total number 
of reactive epitopes and invariant epitopes (see Methods) over study window. n events = 49 increasing to 52 when AgP mutations were considered. 
FBreadth is a subject level measure. cov, covariates. Bold text highlights model P values. RR, relative risk; M, magnitude; %M, percentage magnitude; 
AgP, putative antigen processing mutation. 
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2 factors, %M and epitope entropy (Table 4). Individually, %M 
and entropy informed 39% and 10% of the variation, respectively. 
Notably, as discussed in univariate analysis above, neither protec-
tive HLA allele nor Gag restriction explained any of the variation 
in time to virus escape.
Epitope entropy is an incomplete surrogate for virus fitness. While 
entropy correlated highly significantly with time to escape, inde-
pendently it informed only approximately 10% of the variation 
in time to escape (Table 4). This was surprising given that virus 
fitness should be a major determinant for the ability of mutants 
to emerge. We wondered whether the contribution of entropy to 
virus escape represented a lower estimate for in vivo fitness impact. 
We examined patient CAP239, who generated a subdominant HLA 
B*5801-restricted T cell response that targeted the classical Gag 
240–249 epitope (TW10), which has a low entropy (lowest tertile 
in our data set, see Supplemental Table 1). Escape within this 
epitope occurred within days (usual escape mutant, 242 threonine 
to asparagine mutation [T242N]), compared with slower escape 
in this same epitope observed in other subjects (CH058, CH077; 
Supplemental Table 1). Neither the relative immunodominance 
of the TW10 T cell response in patient CAP239 (15% CAP239 vs. 
17% CH058) nor the M of response was higher than in subject 
CH058, which could have explained more rapid escape (Supple-
mental Table 1). Further examination of the T/F virus in this sub-
ject showed that it already contained upstream Gag mutations, 
H219Q and I223V (Supplemental Table 1). These mutations are 
known to occur more frequently in B*57/58 progressors than in 
nonprogressors and to partially compensate for the fitness cost 
of the T242N escape within the TW10 epitope (51). This likely 
facilitated the more rapid escape observed in this patient, ren-
dering this T cell response less effective than in other B*57/5801 
patients; none of whom had these compensatory mutations in 
their T/F virus (Supplemental Table 1). This exception suggests 
that epitope entropy is a partial surrogate for fitness and empha-
sizes the strength of the relationship between “true” in vivo fitness 
and time to virus escape.
Discussion
Vertical T cell immunodominance and epitope entropy com-
bine to explain nearly half of the variation in the time to HIV-1 
escape from primary CD8+ T cells. This means that within an 
individual, dominant HIV-1–specific T cells must kill or sup-
press virus-infected cells more efficiently than subdominant 
T cells, but the emergence of mutants in some regions of the 
HIV-1 proteome is constrained, significantly slowing the 
rate of escape despite sustained T cell pressure. Importantly, 
these observations were made in acute infection in individu-
als infected with a single T/F virus when HIV-1–specific CD8+ 
T cells are capable of recognizing and killing all circulating 
HIV-1–infected cells. Note that these observations also hold 
if nonlytic mechanisms of selection pressure are attributed to 
HIV-1–specific CD8+ T cells (52). Combined with our previous 
observations showing no difference in polyfunctional profiles 
of dominant versus subdominant T cells (39), our data suggest 
that CD8+ T cells can sustain strong T cell pressure in vivo even 
when the result is slow to no virus escape.
Figure 5
M, immunodominance (%M), 
breadth, and the epitope entropy 
of the HIV-1–specific T cell 
response all contribute to time to 
escape. Univariate correlations 
of time to escape with (A) mag-
nitude (M), (B) %M of the T cell 
response, and (C) T cell breadth 
and (D) entropy of the epitope 
targeted by the T cell response. 
T cell data are restricted to 
the first HIV-1–specific T cell 
responses detected using IFN-γ 
ELISpot detected within 50 days 
of Fiebig stages I/II. Time to virus 
escape was calculated from the 
time of first detection of the T cell 
response and time to 50% change 
in SGA sequences compared 
with the T/F sequence. Data were 
resolved into tertiles in A, B, and 
D and median in C. See Supple-
mental Table 2 for risk ratios and 
P values using CPH models.
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These results are distinct from, and advance on, previous 
papers (e.g., refs. 13, 24). This is the first study to our knowledge 
to comprehensively measure and analyze vertical immunodom-
inant T cell hierarchies in HIV-1 infection and to relate these to 
measurements of longitudinal immune escape. While, our pre-
vious work described acute and rapid virus escape, we did not 
examine or demonstrate the contribution of immunodominance 
or T cell breadth to escape (20, 39). The design of this study 
ensured that all HIV-1–specific T cell responses induced in sub-
jects were quantified and considered for analysis; indeed, almost 
60% of our mapped T cell responses had not been described 
previously. Our results, because they are independent of HLA 
Table 3
Multivariate analysisA reporting RR of T cell response covariates M and %M and entropy on time to T cell escapeB of epitopesC  
with and without putative AgPD
Model Cov for each model Analysis TTE, TTE, TTE + AgP, TTE + AgP, 
   unstratified subject stratified  unstratified subject stratified
     
M/entropy log10(M) RR/cov P 1.8/0.02 4.9/0.01 2/0.007 9.1/0.003
  (RR 95% CI) (1.1, 3.1) (1.4, 17) (1.2, 3.3) (2.1, 39)
 log10(entropy) RR/cov P 4.4/0.006 22/0.003 3.8/0.01 32/0.002
  (RR 95% CI) (1.5, 13) (2.9, 171) (1.3, 11) (3.6, 288)
  Model P value 0.003 3 × 10–4 0.0021 2.8 × 10–5
  P value adding M 0.03 0.01 0.01 0.00
   to entropy
  Interaction termE M 0.80 0.30 0.65 0.43
   & entropy
     
%M/entropy log10(%M) RR/cov P 5.01/0.00004 4.7/0.02 6.6/2 × 10–6 6.8/0.007
  (RR 95% CI) (2.32, 10.81) (1.3, 17) (3, 15) (1.7, 27)
 log10(entropy) RR/cov P 8/18/0.002 22/0.004 6.6/0.004 25/0.004
  (RR 95% CI) (2.22–30.17) (2.6, 187) (1.8, 24) (2.8, 232)
  Model P value 1.7 × 10–6 0.00057 6.4 × 10–8 0.00018
  P value adding %M 0.001 0.01 <0.001 0.002
   to entropy
  Interaction to %M 0.38 0.12 0.72 0.11
   & entropy
     
M/entropy/%M log10(M) RR/cov P 0.96/0.9 –F 0.94, 0.8 –
  (RR 95% CI) (0.54, 1.7)  (0.53, 1.6) 
 log10(entropy) RR/cov P 8.2/0.002  6.5/0.004 
  (RR 95% CI) (2.2, 30)  (1.8, 2.4)
 log10(%M) RR/cov P 5.1/1 × 10–4  6.8/8 × 10–6 
  (RR 95% CI) (2.2, 12)  (3, 16)
  Model P value 7 × 10–6  2.9 × 10–7 
  P value adding %M 0.00009  <0.00001 
   to M/entropy
  Interaction term M 0.08  0.15 
   & %M
     
M/entropy/breadth log10(M) RR/cov P 1.5/0.1 –G 1.6/0.08 –
  (RR 95% CI) (0.88, 2.6)  (0.95, 2.7) 
 log10(entropy) RR/cov P 5/0.005  4.1/0.01 
  (RR 95% CI) (1.6, 15)  (1.4, 12) 
 Breadth RR/cov P 0.87/0.05  0.86/0.03 
  (RR 95% CI) (0.76, 1)  (0.76, 0.99) 
  Model P value 0.0011  0.00048 
  P value adding breadth 0.036  0.019 
   to M/entropy
ACPH test. BTime to escape measured in days from first detection of T cell response (detected in first 50 days from Fiebig stages I/II) to time to ≤50% transmit-
ted virus within reactive epitope. C17 subjects; total epitopes analyzed = 59. DTime to escape measured in days from first detection of T cell response to time 
to ≤50% transmitted virus, where mutation emerges within proximity of T cell epitope, occurring coincident with decline of T cell response. E“Interaction term” 
examines whether the effect of the listed covariates is more than additive. F%M, which ranks the magnitude of individual T cell responses, is redundant in mod-
els that (a) also include M and (b) have data stratified by subject. –, not applicable. GBreadth is a subject level measure. Bold text highlights model P values.
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restriction, are not biased to known T cell epitopes nor are they 
based on theoretical escape sequence footprints (49). Moreover, 
we showed that infecting HIV-1 clade, country of origin, and 
gender did not impact time to escape. Our results are therefore 
broadly generalizable to all subjects infected with HIV-1, whether 
or not they express a protective HLA allele. We show that the 
immune selection pressure exerted on HIV-1 by an individual 
T cell response must be considered in the context of the other 
T cell responses induced at that stage of infection. T cells tar-
geting the same epitope in different individuals will contribute 
more or less to the total T cell immune pressure, dependent on 
whether the response is dominant or subdominant. This may 
reflect competition between different T cell populations, each 
seeing different epitopes on the same infected cell.
It should be noted that we define immunodominance very 
precisely as the magnitude of the response relative to the total 
response within each patient at a given time point. This differs 
from many previous studies in which a response has been called 
“immunodominant” because it occurs repeatedly in patients with 
a given HLA type (e.g., B*57 or B*27), without recognizing that it 
may not be the strongest response at several time points (24, 49). 
This is clearly illustrated for the responses of patients CH058 and 
CH077 to the TW10 immunoprevalent epitope, which was only 
immunodominant in the true sense at some time points and not 
in the first weeks of infection (Figure 2, B and E). Given than both 
T cell mapping approaches afford valuable though different data, 
we suggest in the future that vertical immunodominance studies 
be clearly distinguished from horizontal measures across patients 
that are more accurately investigating immunoprevalence.
This work is distinct from virus challenge models in mice, which, 
while showing protection associated with certain T cell immu-
nodominance hierarchies, use invariant challenge viruses such as 
lymphocytic choriomeningitis virus (53, 54). Those studies high-
lighted the contribution of certain T cell immunodominance hier-
archies to virus control but did not explore how different T cell 
immunodominance hierarchies combine to exert in vivo pressure 
on the infecting virus. Furthermore, the constancy of the infecting 
virus in these earlier animal experiments generated immunodom-
inance hierarchies that were sustained over time, in marked con-
trast to the studies described here for HIV-1 (17).
In our study, subjects are aligned by stage of infection (days from 
Fiebig stages I/II) and therefore exclude the impact of both differ-
ential VL, which can influence T cell function and shifting T cell 
immunodominance patterns. These factors can confound stud-
ies of chronic infection and even studies of early HIV-1 infection. 
Here, deduction of the T/F virus(es) in each subject and subse-
quent virus sequencing were combined with detailed T cell kinet-
ics data to produce by far the most accurate virus escape measure-
ments to date. We show that escape from acute T cell responses 
within the same subjects can range from days to years. We went 
further and applied error modeling to these escape measurements 
to confirm the robustness of our results. Finally, we used multi-
variate analysis to demonstrate conclusively that nearly half of the 
variability in time to escape, which is an in vivo measure of T cell 
pressure, can be explained by just 2 measurements, immunodomi-
nance and entropy. Significantly, measurements of vertical immu-
nodominance alone accounted for 39% of the variability in time to 
escape. The strength of this association shows clearly that vertical 
immunodominance hierarchies in HIV-1 are a major determinant 
of time to virus escape. Given that immunodominance is likely a 
compound consequence of many other variables, it will be impor-
tant to investigate how factors such as polyfunctionality (55) and 
exhaustion profiles (56), lytic (57)/nonlytic control (52), and TCR 
repertoire (58–61) contribute to virus escape.
We were unable to quantify the contribution of these first 
HIV-1–specific T cell responses to decline in VL in acute infection, 
primarily because of insufficiently frequent VL data in these sub-
jects preventing calculation of VL slopes. While it has been shown 
in SIV challenge of macaques that certain T cell immunodomi-
nance hierarchies are associated with VL control, we predict 
HIV-1 control in human infection will be more complex (62, 63). 
In macaques, standardized SIV challenge strains have been used 
across experiments; this differs from HIV-1 infection for which 
every subject’s infection is founded by a different virus (64). Dif-
ferences in T/F virus sequence could impact virus replicative fit-
ness. Epidemiological studies suggest that intrinsic properties of 
the T/F virus account for as much as 50% of the variation in VL set 
point (65, 66). Consistently, in our study, examination of T/F virus 
sequence outside reactive T cell epitopes found that subjects with 
lower acute VL set points contained footprints of previous virus 
escape in B57/5801, B81, and B51 epitopes (Supplemental Table 1 
and refs. 67, 68). These escape variants have been associated with 
lower in vitro replication, suggesting the transmitted viruses of 
these subjects had poorer replicative fitness, which contributed to 
the lower set point VL observed in some subjects (37, 64–68). Stud-
ies are ongoing in an extended patient set to examine associations 
of T cell responses with VL over the first 6 months of HIV-1 infec-
tion. The changing patterns of T cell immunodominance during 
this period will exert variable pressure, which will have to be incor-
porated into a model.
Table 4
%M and epitope entropy combine to explain nearly half of the of the variation in time to escape of epitopesA
CPH modelB Cov  TTE, unstratified TTE + AgPC, unstratified
Univariate log10(%M) %(ρ2n)D 29% 39%
 Breadth %(ρ2n) 13% 26%
 log10(entropy) %(ρ2n) 13% 10%
Multivariate log10(%M)/ %(ρ2n) 43% 48%
  log10(entropy)   
A17 subjects; epitopes analyzed = 57; invariant epitopes/ censored events =10. BCPH test. CTime to escape measured in days from first detection of T cell 
response to time to ≤50% transmitted virus, where mutation emerges within proximity of T cell epitope, occurring coincident with decline of T cell response. 
Dρ2n proportion of total variance (= 1) in CPH test explained by listed covariate (50), expressed as a percentage.
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Methods
Patients and samples. Acute infection was defined as a positive for HIV-1 
vRNA in plasma but negative or equivocal for HIV-1 serology at a screen-
ing visit. Patients were bled at multiple time points over 1 to 3 years. See 
Table 1 and Supplemental Table 1 for the demographical and clinical data 
for each patient. VL set point was determined using an average of VLs 
within a “set point window” (2). Patients were aligned using days from 
Fiebig stages I/II. Days after Fiebig stages I/II were estimated for a subset 
of subjects who were first detected slightly later in Fiebig stages III and IV 
(Fiebig stage III = 7 days after Fiebig stages I/II; Fiebig stage IV = 11 days 
after Fiebig stages I/II; ref. 46).
Virus sequencing. RNA extraction, complementary DNA synthesis, 
and SGA have been described previously (70, 71). The T/F virus(es) was 
deduced in the overlapping 5′ and 3′ halves for each subject from plasma 
collected in Fiebig stages I–IV. For the bulk of subjects (15 out of 17), serial 
SGA sequencing was performed approximately 4, 8, 24, and 60 weeks fol-
lowing subject screening. For 2 subjects, more limited screening (1 time 
point within 8 weeks of screening) was performed because of either early 
ART treatment (subject CH607) or strong and sustained VL control <40 
copies vRNA per ml (subject CH067), which prevented successful ampli-
fication of single virus genomes. For 9 out of 17 subjects, samples were 
also available for additional sequencing at time points between 2 and 3 
years from screening.
T cell mapping. 18-mer peptides overlapping by 10 amino acids were 
synthesized (Sigma-Genosys or MRC Human Immunology Unit, 
Weatherall Institute of Molecular Medicine) to match the transmitted 
sequence of each subject. Approximately 400 peptides for each patient 
(including >200 that were unique to that patient) were arranged into 
pools in a matrix format using the Peptide Portal program (SCHARP), 
adapting code from the Deconvolute this! program (72). Each peptide 
was repeated 4 times in the matrix peptide plate. Cryopreserved PBMCs 
were thawed and rested for 2 hours before being placed in the ELISpot 
plates (Merck, Millipore) at 1 × 105 cells per well. Antigens in the peptide 
plates were mixed with 1:1 with PBMCs in the ELISpot plate to a final 
concentration of 2 or 5 μg/ml and incubated for 20 hours at 37°C, 5% 
CO2. Coating, development (MabTech), and reading of ELISpot plates 
(AID Reader) has been described previously (73). At this stage, 30 SFU per 
106 PBMCs and >3× background threshold of positivity was applied to 
peptide pools to maximize sensitivity. Data from positive pools were then 
deconvoluted (72) to identify candidate epitope peptides. Putative posi-
tive 18-mer peptide–specific T cell responses were confirmed in triplicate 
in a follow-up IFN-γ ELISpot with 1 × 105 cells per well and a peptide con-
centration of 2 μg/ml with 4 to 6 negative control wells (media only) and 
at least 1 positive control well (10 μg/ml PHA; Sigma-Aldrich) together. 
Positive T cell responses were defined as ≥30 SFU per million, more than 
4 times background. Zero values were not accepted in any replicate of 
antigen-stimulated wells.
LANL ELF software was then used to identify HLA-matched known and 
predicted CTL epitopes (http://www.hiv.lanl.gov/content/sequence/ELF/
epitope_analyzer.html). These 9- to 11-mer peptides were then synthesized 
and tested using ELISpot, applying the same positivity criteria described 
above. Optimal epitopes were defined for 58% of reactive 18-mer peptides 
(see Supplemental Table 1). For univariate and multivariate analysis, data 
from the experimentally confirmed optimal epitope was used in preference 
to corresponding 18-mer data.
HLA typing. HLA typing (Weatherall Institute of Molecular Medicine) 
was performed using the sequence-specific primer method adapted 
from ref. 74 that uses allele-specific primer combination in PCR ampli-
fication to provide absolute HLA resolution to 2 digits and high-prob-
ability resolution to 4 digits.
These results have practical implications for T cell vaccine 
design. Although nothing can be done to influence the nature 
of the actual T/F virus, thereafter vaccination could influence 
events profoundly. Our data show that the fitness loss to HIV-1 
of some mutations is so great that the virus will endure ongo-
ing killing or viral suppression by immunodominant CD8+ 
T cells, often for years. In our data set, in primary infection 
most of the immunodominant T cell responses targeted high 
entropy regions of HIV-1, often in Nef and Env, and escape was 
very rapid. Low entropy epitopes were also targeted, but these 
responses were typically subdominant. We argue that the host 
T cell response in natural infection, which targets both low 
and high entropy epitopes, with the latter more likely to be 
immunodominant early on, explains partly the failure to clear 
the virus. Our data support vaccine immunogens that focus 
on conserved regions of HIV-1 but possibly excluding the Pol 
protein, which was poorly immunogenic in acute HIV-1 infec-
tion. This approach would ensure, regardless of the immu-
nodominance hierarchy established in individual vaccinees, 
that all T cell responses would be focused on conserved regions 
of HIV-1, minimizing rapid, early escape. Induction of broad 
T cell responses is particularly important in HIV-1 to maximize 
the likelihood of vaccine-induced T cell response recognizing 
highly variable infecting viruses. However, our observations 
demonstrated that increased T cell breadth often occurs at the 
cost of immunodominance, because immunodominant T cell 
responses targeted to high entropy epitopes would out-compete 
subdominant responses that recognize lower entropy epitopes, 
resulting in rapid virus escape and less sustained T cell pressure. 
This suggests that, in some subjects, high T cell breadth may 
be detrimental to HIV-1 control. Notably, successful induction 
of broad T cell responses against a conserved HIV-1 immuno-
gen would satisfy both the need to maximize T cell detection 
of incoming viruses and to overcome any detrimental effect 
of breadth on immunodominance, because, even if an epitope 
escapes, the next T cell response would also likely focus on a low 
entropy epitope.
Another important implication that comes from these data is 
that measuring T cell responses to pools of HIV-1 peptides is not 
adequate to test immunogenicity of HIV-1 T cell vaccines. Better 
predictions of vaccine efficacy could be made by mapping of indi-
vidual vaccine-induced T cell responses to define immunodomi-
nance hierarchies, breadth, and epitope entropy. This approach 
would enable identification of those vaccinees who have domi-
nant T cell responses targeting low entropy regions of HIV-1 and 
who therefore have the greatest likelihood of exerting significant 
and sustained T cell pressure in the first weeks of subsequent 
HIV-1 infection.
The observation of virus escape in HIV-1, first described over 
20 years ago (28), has been the focus of numerous studies inves-
tigating escape to understand in vivo immune pressure exerted 
by T cells on HIV-1 (69). In this study, we have explained virus 
escape, showing that almost half of all the variability of time 
to escape is determined by just 2 factors — immunodominance 
and epitope entropy. This study therefore simplifies the field. 
Factors, such as polyfunctionality, T cell exhaustion, and T cell 
receptor hierarchies, that have been previously proposed as inde-
pendent determinants of in vivo T cell pressure in HIV-1 could 
play roles but more likely only when they work in the context of 
vertical T cell immunodominance.
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Where no mutations emerged, the peptide was split into nonoverlapping 
9-mers, and the average of entropies for each 9-mer was calculated.
Statistics. The relationship between several covariates and an outcome vari-
able, “time to escape” (see above), with and without 3 AgP mutations was 
examined. In order to estimate RRs, CPH models were fitted to data. A uni-
variate model for each covariate was fitted to data, and those significantly 
associated with time to escape (P ≤ 0.05) were considered in multivariate 
models. Both nonstratified and subject-stratified models were fitted. To 
better characterize the relative effect sizes across covariates, each covariate 
was also binned into tertiles and entered as a categorical covariate into the 
regression model, with the first tertile serving as the reference group. P val-
ues of less than 0.05 were considered significant. To determine how much of 
the variation in time to escape was determined by %M, breadth, and entropy, 
we applied the O’Quigley model ρ2n (50), which is a modified version of the 
generalized linear R2 equation (75) that replaces total number of observa-
tions with the number of noncensored observations. 
Study approval. Subjects gave full written informed consent to enroll into 
the acute infection arms of the CHAVI 001 cohort (OXTREC 3306, Oxford) 
and Centre for AIDS Programme Research in South Africa (CAPRISA) 002 
(Research Ethics Committee, Faculty of Health Sciences, UCT REC no. 
025/2004, Capetown). Approval for these experiments has also been given 
by OXTREC 3306, Oxford. 
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Time to escape calculations. Peptides and substitutions were aligned relative 
to HXB2 standards (http://www.hiv.lanl.gov/content/sequence/QUICK_
ALIGN/QuickAlign.html). Virus escape within the reactive epitope was 
defined as ns mutations occurring with ≥50% change in SGA sequences 
compared to the founder T/F virus sequence. ns mutant epitopes elicited 
an attenuated response (see Supplemental Table 1) when tested in ex vivo 
IFN-γ ELISpots (cells permitting) in comparison to the T/F epitope; oth-
erwise an attenuated response was assumed. An AgP mutation was iden-
tified when a decline in magnitude of the T cell response was observed 
subsequent to the emergence of ns mutations occurring in close proximity 
(≤20 amino acids 5′ or 3′) to the reactive epitope.
Time to escape was calculated as the time in days from first detection 
of the selecting T cell response to virus escape in the reactive epitope. 
This latter time point was determined using the gradient of the trend 
line (Excel, Microsoft) between (a) the last visit when the T/F sequence 
was found in >50% of SGA sequences generated and (b) the subsequent 
time point when the proportion of T/F sequences within the reactive 
peptide fell below 50%. These data were used for all CPH tests. The term 
“invariant” epitope indicates that the percentage of T/F sequences cor-
responding to the reactive peptide remained >50% across all sequencing 
time points generated from a minimum sequencing window of ≥200 days 
from subject’s initial screening visit.
Entropy calculations. A Shannon entropy score was calculated for all reac-
tive peptides in this study (40). Entropy was calculated for experimentally 
confirmed optimal epitopes or for predicted 9-mers epitopes where the 
optimal was not known (see Supplemental Figure 3 for details).
For each epitope, the LANL sequence database was used to identify 
all known sequences that belong to the same HIV-1 clade that infected 
the responding participant. Data were limited to one randomly selected 
sequence per patient, and sequences defined as “problematic” by the LANL 
database search tool were omitted. Between 516 and 43,538 sequences 
were analyzed per epitope. To focus the analysis on peptides as they appear 
to T cell receptors, all gaps within sequences were removed. Sequences 
were aligned and gaps included at either terminus to maximize similar-
ity between sequences. Stop codons, and any sequence downstream, were 
stripped and replaced with gaps. Gaps were treated as a separate symbol. 
The Shannon entropy of each position in the epitope measured in nats was 
then calculated with the following formula (–∑ni=1pilogepi), where pi stands 
for the frequency of a given amino acid at position i. The mean of these 
scores was used as the epitope entropy.
Rules were defined to predict the location of 9-mer T cell epitopes in reac-
tive 18-mer peptides. Predicted 9-mers were centered on residues where ns 
changes from the T/F emerged over time and mean entropy calculated. 
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